TransMedics Group, Inc. (NASDAQ:TMDX) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of TransMedics Group, Inc. (NASDAQ:TMDX) have received an average rating of “Moderate Buy” from the eleven research firms that are covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $131.80.

A number of equities research analysts have commented on TMDX shares. Robert W. Baird dropped their price objective on shares of TransMedics Group from $200.00 to $150.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 29th. Stephens increased their target price on TransMedics Group from $151.00 to $178.00 and gave the company an “overweight” rating in a report on Friday, August 2nd. Piper Sandler cut their price target on TransMedics Group from $180.00 to $110.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 20th. Canaccord Genuity Group lowered their price objective on TransMedics Group from $109.00 to $104.00 and set a “buy” rating for the company in a research report on Wednesday, November 20th. Finally, JPMorgan Chase & Co. cut their target price on TransMedics Group from $173.00 to $116.00 and set an “overweight” rating on the stock in a research report on Tuesday, October 29th.

TransMedics Group Trading Up 8.1 %

TMDX opened at $87.11 on Friday. The business has a fifty day moving average price of $113.26 and a 200 day moving average price of $136.45. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33. TransMedics Group has a 12 month low of $67.77 and a 12 month high of $177.37. The stock has a market capitalization of $2.92 billion, a price-to-earnings ratio of 92.67 and a beta of 2.08.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings data on Monday, October 28th. The company reported $0.12 EPS for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.17). TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The company had revenue of $108.76 million for the quarter, compared to analyst estimates of $115.00 million. During the same period in the prior year, the firm posted ($0.12) earnings per share. The business’s quarterly revenue was up 63.7% compared to the same quarter last year. Sell-side analysts expect that TransMedics Group will post 1 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Edward M. Basile sold 6,750 shares of the company’s stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $83.55, for a total value of $563,962.50. Following the completion of the sale, the director now directly owns 732 shares of the company’s stock, valued at approximately $61,158.60. This represents a 90.22 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Waleed H. Hassanein sold 8,625 shares of the stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $132.71, for a total transaction of $1,144,623.75. Following the sale, the chief executive officer now owns 61,643 shares of the company’s stock, valued at $8,180,642.53. This trade represents a 12.27 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 26,958 shares of company stock worth $3,470,328 in the last quarter. 7.00% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of TMDX. Vaughan Nelson Investment Management L.P. purchased a new position in TransMedics Group in the 2nd quarter valued at $39,862,000. Driehaus Capital Management LLC lifted its stake in shares of TransMedics Group by 15.8% in the 2nd quarter. Driehaus Capital Management LLC now owns 1,486,073 shares of the company’s stock worth $223,832,000 after acquiring an additional 202,867 shares during the period. Principal Financial Group Inc. boosted its holdings in shares of TransMedics Group by 260.1% in the third quarter. Principal Financial Group Inc. now owns 202,287 shares of the company’s stock valued at $31,759,000 after acquiring an additional 146,115 shares in the last quarter. Hood River Capital Management LLC acquired a new position in shares of TransMedics Group during the second quarter worth about $18,854,000. Finally, Canada Pension Plan Investment Board purchased a new position in TransMedics Group during the second quarter worth about $16,086,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.